Related Experiment Video
Updated: Mar 11, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
13.7K
Glaucoma: Hot Topics in Pharmacology
Shiama I Balendra1, Parth Arvind Shah2, Mishank Jain3
1Glaucoma and Retinal Neurodegeneration Group, Department of Visual Neuroscience, UCL Institute of Ophthalmology, London. United Kingdom.
Current Pharmaceutical Design
|November 30, 2016
Summary
Glaucoma research focuses on identifying risk factors, improving early diagnosis, and developing novel treatments like Rho kinase inhibitors and minimally invasive surgery to prevent vision loss. New drug delivery methods enhance patient adherence to treatment regimens.
Area of Science:
- Ophthalmology
- Neuroscience
Background:
- Glaucoma is a group of neurodegenerative diseases causing retinal ganglion cell death.
- Affecting nearly 80 million globally, many remain undiagnosed until irreversible blindness occurs.
- Research priorities include risk factor identification, early diagnostics, and novel therapies.
Purpose of the Study:
- To review recent advancements in glaucoma research.
- Focus areas include risk factors, diagnostic tools, and therapeutic interventions.
- Summarize latest findings on glaucoma management and neuroprotection.
Main Methods:
- Literature search of PubMed using keywords related to glaucoma risk factors, diagnostics, and treatment.
- Analysis of current evidence on risk factors, diagnostic technologies, and treatment modalities.
- Review of emerging therapies, including drug delivery systems and surgical techniques.
Main Results:
- Identified risk factors include low cerebrospinal fluid pressure, smoking, vascular issues, and light toxicity.
- Advanced diagnostics like SD-OCT, DARC, and IOP telemetry are highlighted.
- Emerging treatments include Rho kinase inhibitors, neurotrophic agents, and Minimally Invasive Glaucoma Surgery (MIGS) devices.
Conclusions:
- Future glaucoma management aims to reduce risk factors, enable early diagnosis, and reverse neurodegeneration.
- Novel treatments focus on lowering intraocular pressure (IOP) and providing neuroprotection.
- Combination therapies and advanced drug delivery systems offer improved patient outcomes and adherence.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:25Glaucoma: Overview
1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
01:28Angle Closure Glaucoma: Treatment
1.5K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
782
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
782
01:23Ophthalmic Drug Delivery Systems
152
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
152
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.5K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.5K